Taken only once a day at a dosage of 120 mg, gilteritinib demonstrated an encouraging cCR of 30% as single agent in 252 r/r AML patients (with a cCR rate of 41% and a CR rate of 11% in 169 FLT3 ITD and TKD mutant patients) [54]. This evidence concerns the gene FLT3 and acute myeloid leukemia.